Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

NCT03777085 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: TQB2303
DRUG: Rituximab

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.